X4 Pharmaceuticals (XFOR) Price & Analysis

Compare

1,088 Followers

XFOR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.35 - $26.84

Previous CloseN/A

Volume769.31K

Average Volume (3M)589.57K

Market Cap

$77.23M

Enterprise Value$29.16M

Total Cash (Recent Filing)$62.95M

Total Debt (Recent Filing)$2.18M

Price to Earnings (P/E)0.7

Beta1.56

Next Earnings

Nov 06, 2025

EPS Estimate

-0.55

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.47

Shares Outstanding22,449,133

10 Day Avg. Volume343,784

30 Day Avg. Volume589,573

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue0.89

Enterprise Value/Gross Profit1.07

Enterprise Value/Ebitda-0.31

Forecast

1Y Price Target

$6.25

Price Target Upside88.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial HealthThe $60M private placement not only strengthens the company's balance sheet but also aids in meeting loan covenant obligations.

Leadership ChangesThe appointment of new C-suite management and board of directors, including experienced leaders from CTI BioPharma, is expected to strengthen X4 Pharmaceuticals' position.

Revenue PerformanceThe company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.

Bears Say

Market ChallengesThe analyst is taking a more conservative view of the launch trajectory and commercial opportunity in WHIM syndrome, leading to lowered estimates.

Stock AdjustmentsThe company enacted a reverse stock split effective April 28; accordingly, the price target is adjusted to $7 based on the updated outstanding share count.

X4 Pharmaceuticals News

Altimmune appoints Christophe Arbet-Engels as CMO

Altimmune (ALT) announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025....

11d ago

ALT

XFOR

X4 Pharmaceuticals announces restructuring, 50% reduction in workforce

X4 Pharmaceuticals (XFOR) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s...

23d ago

XFOR

X4 Pharmaceuticals Announces Major Strategic Restructuring

X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On September 17, 2025, X4 Pharmaceuticals announced a strategic...

23d ago

XFOR

X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders

16:17 EDT X4 Pharmaceuticals (XFOR) files to sell 59.89M shares of common stock for holders Published first on...

1M ago

XFOR

X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $9 from $30 and...

1M ago

XFOR

X4 Pharmaceuticals Announces Board Resignations and Appointments

The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 22, 2025, X4 Pharmaceuticals, Inc....

2M ago

XFOR

3 Penny Stocks to Watch Now, 8/14/25

Momentus, X4 Pharmaceuticals, and ReShape Lifesciences are the 3 Penny Stocks to watch on August 14, 2025, based on TipRanks’ Penny...

2M ago

MNTS

RSLS

X4 Pharmaceuticals Closes $85M Private Placement Deal

The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 13, 2025, X4 Pharmaceuticals announced...

2M ago

XFOR

X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $3.50 from $7...

2M ago

XFOR

X4 Pharmaceuticals trading halted, news pending

15:37 EDT X4 Pharmaceuticals (XFOR) trading halted, news pending Published first on TheFly – the ultimate source for...

2M ago

XFOR

X4 Pharmaceuticals Announces $60M Equity Financing

X4 Pharmaceuticals ( ($XFOR) ) has provided an announcement. On August 12, 2025, X4 Pharmaceuticals announced a $60...

2M ago

XFOR

X4 Pharmaceuticals announces $60M financing, management changes

X4 Pharmaceuticals (XFOR) has entered into a securities purchase agreement for a private placement in public equity financing...

2M ago

XFOR

X4 Pharmaceuticals Advances Phase 3 Study for WHIM Syndrome Treatment

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals is conducting a...

2M ago

XFOR

X4 Pharmaceuticals Advances Phase 3 Study of Mavorixafor for WHIM Syndrome

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals is conducting a...

2M ago

XFOR

XFOR FAQ

What was X4 Pharmaceuticals Inc’s price range in the past 12 months?

X4 Pharmaceuticals Inc lowest stock price was $1.35 and its highest was $26.84 in the past 12 months.

What is X4 Pharmaceuticals Inc’s market cap?

X4 Pharmaceuticals Inc’s market cap is $77.23M.

When is X4 Pharmaceuticals Inc’s upcoming earnings report date?

X4 Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2025 which is in 27 days.

How were X4 Pharmaceuticals Inc’s earnings last quarter?

X4 Pharmaceuticals Inc released its earnings results on Jul 31, 2025. The company reported -$3.47 earnings per share for the quarter, missing the consensus estimate of -$3.368 by -$0.102.

Is X4 Pharmaceuticals Inc overvalued?

According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does X4 Pharmaceuticals Inc pay dividends?

X4 Pharmaceuticals Inc does not currently pay dividends.

What is X4 Pharmaceuticals Inc’s EPS estimate?

X4 Pharmaceuticals Inc’s EPS estimate is -0.55.

How many shares outstanding does X4 Pharmaceuticals Inc have?

X4 Pharmaceuticals Inc has 22,449,133 shares outstanding.

What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?

X4 Pharmaceuticals Inc reported an EPS of -$3.47 in its last earnings report, missing expectations of -$3.368. Following the earnings report the stock price went down -5.085%.

Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in XFOR

X4 Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-207.22%

Trailing 12-Months

Asset Growth

-50.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on diseases characterized by disruptions in immune cell trafficking, including certain types of primary immunodeficiencies. X4's lead product candidate, mavorixafor, is being developed to treat a range of conditions linked to this mechanism, such as WHIM syndrome, a rare immune disorder.

X4 Pharmaceuticals (XFOR) Earnings & Revenues

Historic Earnings Reports

XFOR Stock 12 Month Forecast

Average Price Target

$6.25

▲(88.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","43":"$43","10.75":"$10.75","21.5":"$21.5","32.25":"$32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,10.75,21.5,32.25,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,2.1692307692307695,2.7384615384615385,3.3076923076923075,3.876923076923077,4.446153846153846,5.015384615384615,5.584615384615384,6.153846153846153,6.723076923076922,7.292307692307691,7.861538461538462,8.430769230769231,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,1.9576923076923078,2.3153846153846156,2.6730769230769234,3.0307692307692307,3.388461538461539,3.746153846153846,4.103846153846154,4.461538461538462,4.819230769230769,5.176923076923077,5.534615384615385,5.892307692307693,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.6,1.7461538461538462,1.8923076923076922,2.0384615384615383,2.184615384615385,2.3307692307692305,2.476923076923077,2.623076923076923,2.769230769230769,2.9153846153846152,3.0615384615384613,3.207692307692308,3.3538461538461535,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.3,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.3,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.57,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >